pembrolizumab
merck
['keynote189', 'lcsm,(-blcsm)', 'key,note,57']
keynote189; 5y update 19% 5y landmark. 86% orr on 57 pts rechallenge after 35#. important to appreciate 5y pfs landmark = 7.5% so most need more cancer treatment #esmo22 #lcsm 
Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden.